A Study on Sensorineural Hearing Loss Induced by Chemoradiotherapy for Head and Neck Cancers Using Cisplatin

Kitoh Ryosuke, Mori Kentaro, Kitano Tomohiro, Usami Shin-ichi

doi:10.5631/jibirin.109.233

Bibliographic Information

Other Title

シスプラチンを用いた化学放射線療法の聴力変化の検討
臨床シスプラチンを用いた化学放射線療法の聴力変化の検討
リンショウシスプラチンオモチイタカガクホウシャセンリョウホウノチョウリョクヘンカノケントウ

Search this article

Description

Cisplatin (CDDP) is widely used as an effective antineoplastic drug for cancers of various organs, and is also known to cause ototoxicity. In this study, we report on the incidence of and factors related to CDDP-induced hearing loss, and the time-dependent change of the hearing level among these patients.<br/>Twenty patients with head and neck cancers treated with chemoradiotherapy using CDDP in our institution were enrolled and analyzed. As chemotherapy, three cycles of concurrent CDDP were administered on weeks 1, 4, and 7 of radiotherapy. Pure-tone audiograms were performed before and 1 week after each course of administration of the CDDP. Adverse events including hearing impairment were assessed through the National Cancer Institute Common Toxicity Criteria (NCI CTCAE) v4.0.<br/>The incidence of hearing loss was 45% in this patient group (Grade1 was reported in 6 patients, and Grade2 was reported in 3 patients). Hearing thresholds at 8 kHz were remarkably worse than at any other frequencies. Furtheremore, hearing loss related to creatinine increased and the white blood cell count decreased.<br/>These results indicate that there were individual differences, for example drug metabolism-related factors, related to CDDP-induced hearing loss.

Journal

Practica Oto-Rhino-Laryngologica

Practica Oto-Rhino-Laryngologica 109 (4), 233-238, 2016

The Society of Practical Otolaryngology

Keywords

Details 詳細情報について

Export